Skip to Content

Gilead Seeks FDA Approval for Remdesivir

TUESDAY, Aug. 11, 2020 -- Gilead Sciences has applied to the U.S. Food and Drug Administration for approval for its COVID-19 treatment, remdesivir. The antiviral drug will take the brand name Veklury, the company said.

"Today's filing is an important milestone as we continue to partner with the U.S. government and health care authorities around the globe to address the treatment needs of patients with COVID-19," Merdad Parsey, M.D., Ph.D., Gilead's chief medical officer, said in a statement.

At the moment, remdesivir is available on an emergency basis for hospitalized patients with severe COVID-19. If the FDA approves it, however, the drug will gain wider use. Remdesivir is already approved in Europe and Japan. The request for approval comes after the results of a phase 3 trial. The drug works by blocking the virus from copying itself. Trials of the drug showed that it can cut recovery time from COVID-19 by nearly a third.

"Since the beginning of the pandemic, Gilead has worked with urgency to establish the efficacy and safety profile of Veklury, and we now have a robust data set supporting the evaluation of use of the drug across a range of hospitalized COVID-19 patient populations," Parsey said.

More Information

© 2020 HealthDay. All rights reserved.

Posted: August 2020

Read this next

SARS-CoV-2 Mortality Mainly Linked to Older Age, Comorbidity

WEDNESDAY, Sept. 23, 2020 -- For U.S. veterans with COVID-19, mortality is mainly associated with older age, male sex, and comorbidity, according to a study published online Sept....

Red Blood Cell Distribution Width, Mortality Tied in COVID-19

WEDNESDAY, Sept. 23, 2020 -- For patients with COVID-19, elevated red blood cell distribution width (RDW) is associated with increased mortality risk, according to a study...

Most People With SARS-CoV-2 Do Not Remain Asymptomatic

WEDNESDAY, Sept. 23, 2020 -- Most people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) do not remain asymptomatic, and the secondary attack rate is...